Lantheus Holdings And POINT Biopharma Announced Lu-PNT2002 Phase 3 SPLASH Study Results

(RTTNews) - Lantheus Holdings, Inc. (LNTH) and POINT Biopharma Global Inc. have jointly announced that the Phase 3 SPLASH study evaluating the efficacy and safety of Lu-PNT2002, has met its primary endpoint.

Lu-PNT2002 is a PSMA-targeted, lutetium 177-based radioligand therapy (RLT) candidate, in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed ARPI therapy.

The study has shown that Lu-PNT2002 is a highly effective treatment option for patients suffering from mCRPC, with a statistically significant reduction in the risk of radiographic progression or death.

The SPLASH trial demonstrated a median radiographic progression-free survival (rPFS) per blinded independent central review of 9.5 months for patients treated with Lu-PNT2002, in comparison to 6.0 months for patients treated with ARPI.

The results of the study indicate a 29% reduction in the risk of radiographic progression or death.